Dana Pizzuti Sells 14,375 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) insider Dana Pizzuti sold 14,375 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $44.47, for a total value of $639,256.25. Following the completion of the transaction, the insider now owns 27,786 shares in the company, valued at approximately $1,235,643.42. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Dana Pizzuti also recently made the following trade(s):

• On Wednesday, March 20th, Dana Pizzuti sold 15,089 shares of Crinetics Pharmaceuticals stock. The shares were sold at an average price of $44.06, for a total value of $664,821.34.

Crinetics Pharmaceuticals Trading Down 0.1 %

Crinetics Pharmaceuticals stock opened at $42.97 on Friday. The stock has a 50 day moving average of $42.42 and a two-hundred day moving average of $36.10. The stock has a market capitalization of $2.99 billion, a price-to-earnings ratio of -11.61 and a beta of 0.63. Crinetics Pharmaceuticals, Inc. has a twelve month low of $15.76 and a twelve month high of $49.58.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.01). Crinetics Pharmaceuticals had a negative net margin of 4,223.27% and a negative return on equity of 52.93%. The business’s revenue for the quarter was down 100.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.84) earnings per share. Equities analysts predict that Crinetics Pharmaceuticals, Inc. will post -3.34 earnings per share for the current year.

Analysts Set New Price Targets

CRNX has been the topic of a number of recent analyst reports. Jonestrading increased their price objective on Crinetics Pharmaceuticals from $52.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday, March 20th. Robert W. Baird raised their price target on Crinetics Pharmaceuticals from $45.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, February 29th. Citigroup initiated coverage on Crinetics Pharmaceuticals in a research note on Wednesday, March 6th. They set a “buy” rating and a $68.00 price target on the stock. Oppenheimer raised their price target on Crinetics Pharmaceuticals from $54.00 to $55.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 20th. Finally, HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Crinetics Pharmaceuticals in a research note on Tuesday, March 19th. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $54.17.

Institutional Trading of Crinetics Pharmaceuticals

Several hedge funds have recently modified their holdings of the business. BlackRock Inc. lifted its holdings in shares of Crinetics Pharmaceuticals by 16.3% in the 2nd quarter. BlackRock Inc. now owns 4,600,486 shares of the company’s stock valued at $82,901,000 after buying an additional 644,128 shares during the period. Wellington Management Group LLP raised its holdings in Crinetics Pharmaceuticals by 1.1% during the third quarter. Wellington Management Group LLP now owns 3,640,235 shares of the company’s stock worth $108,261,000 after purchasing an additional 38,523 shares during the last quarter. Vanguard Group Inc. raised its holdings in Crinetics Pharmaceuticals by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 3,502,452 shares of the company’s stock worth $124,617,000 after purchasing an additional 95,417 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Crinetics Pharmaceuticals by 16.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,008,858 shares of the company’s stock worth $107,056,000 after purchasing an additional 430,659 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in Crinetics Pharmaceuticals by 77.7% during the fourth quarter. Jennison Associates LLC now owns 2,547,683 shares of the company’s stock worth $90,647,000 after purchasing an additional 1,113,992 shares during the last quarter. 98.51% of the stock is owned by institutional investors and hedge funds.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.